Skip Navigation

Annals of Oncology 2008 19(2):199; doi:10.1093/annonc/mdm605
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in Ann Oncol
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2008 European Society for Medical Oncology. For Permissions, please email: journals.permissions@oxfordjournals.org

in this issue

in this issue

The first 10% of the full text of this article appears below.


   Phosphorylated AKT in breast cancer
 
AKT phosphorylation is a critical step in the activation of growth factor receptors and can mediate tumor resistance to anthracyclines. Although activation of the AKT pathway appears to be a potentially major event in the survival of breast cancer cells, few studies have investigated its prognostic and predictive value in tissue from breast cancer patients. In this issue, Andre et al. [315–320] report the results of study that aimed to evaluate the frequency of AKT activation in HER2-positive and . . . [Full Text of this Article]


   FDG-PET response evaluation in colon cancer
 

   Chemotherapy in ocular adnexal lymphoma
 

   Glycemic index, glycemic load and thyroid cancer
 

   Quote
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in Ann Oncol:

Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer
F. Andre, R. Nahta, R. Conforti, T. Boulet, M. Aziz, L. X. H. Yuan, F. Meslin, M. Spielmann, G. Tomasic, L. Pusztai, G. N. Hortobagyi, S. Michiels, S. Delaloge, and F. J. Esteva
Ann Oncol 2008 19: 315-320. [Abstract] [Full Text]  

Chemotherapy response evaluation with FDG–PET in patients with colorectal cancer
L.F. de Geus-Oei, H. W. M. van Laarhoven, E. P. Visser, R. Hermsen, B. A. van Hoorn, Y. J. L. Kamm, P. F. M. Krabbe, F. H. M. Corstens, C. J. A. Punt, and W. J. G. Oyen
Ann Oncol 2008 19: 348-352. [Abstract] [Full Text]  

Efficacy of chemotherapy as a first-line treatment in ocular adnexal extranodal marginal zone B-cell lymphoma
E.-K. Song, S.-Y. Kim, T. M. Kim, K.-W. Lee, T. Yun, I.-I. Na, H. Shin, S. H. Lee, D. W. Kim, S. I. Khwarg, and D. S. Heo
Ann Oncol 2008 19: 242-246. [Abstract] [Full Text]  

Glycemic index, glycemic load and thyroid cancer risk
G. Randi, M. Ferraroni, R. Talamini, W. Garavello, S. Deandrea, A. Decarli, S. Franceschi, and C. La Vecchia
Ann Oncol 2008 19: 380-383. [Abstract] [Full Text]